*The following content is generated by AI and is for reference only.
Solifenacin Succinate is a potent, orally active antimuscarinic agent widely utilized in the clinical management of overactive bladder (OAB) syndrome. Chemically known as Solifenacin Succinate, its molecular formula is C24H30FNO4·C4H6O4, reflecting the combination of the active solifenacin base with succinic acid to enhance stability and solubility. The specific CAS number for this salt form is 219385-16-7. This compound acts primarily as a selective antagonist at muscarinic M3 receptors located on the detrusor muscle of the urinary bladder. By blocking these receptors, it effectively inhibits involuntary bladder contractions, thereby increasing bladder capacity and reducing the frequency of urgent urination episodes.
The therapeutic efficacy of Solifenacin Succinate has been established through extensive clinical trials, making it a first-line treatment for patients suffering from symptoms such as urinary urgency, frequency, and urge incontinence. Its high selectivity for the M3 receptor over other muscarinic subtypes contributes to a favorable side-effect profile compared to older, non-selective anticholinergics, although common adverse events like dry mouth and constipation may still occur due to systemic absorption. The drug is typically administered once daily in tablet form, offering convenience and improved patient compliance for chronic management.
Pharmacokinetically, Solifenacin Succinate demonstrates good oral bioavailability with a long half-life that supports once-daily dosing regimens. It undergoes hepatic metabolism, primarily via the cytochrome P450 3A4 enzyme system, necessitating dose adjustments or caution when co-administered with strong CYP3A4 inhibitors. Beyond its primary urological indication, research continues to explore potential off-label applications, though current regulatory approvals focus strictly on OAB. As a generic pharmaceutical ingredient, it remains a cornerstone in modern urology, providing significant relief to millions of patients worldwide by restoring quality of life through effective symptom control. Its development represents a major advancement in targeted receptor therapy for lower urinary tract disorders.